Stockscreener 앱 받기
24.79
0.60%
-0.15
시간 외 거래:
24.70
-0.09
-0.36%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
What drives Nektar Therapeutics stock priceBreakout portfolio performance - jammulinksnews.com
Nektar Therapeutics Stock Analysis and ForecastHigh-return market picks - Autocar Professional
Is Nektar Therapeutics a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com
What analysts say about Nektar Therapeutics stockFree Capital Efficiency Planning - jammulinksnews.com
Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin - MSN
Why Nektar Therapeutics Stock Dived by 3% Today - AOL.com
Nektar Therapeutics Announces Pricing of $100 Million Public Offering - 富途牛牛
B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi - Barchart.com
Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Yahoo Finance
Rezpegaldesleukin Potentially Promising for Atopic Dermatitis - AJMC
5 Second-Half Biopharma Milestones To Watch - BioSpace
Nektar Therapeutics' experimental eczema drug meets main goal of mid-stage trial - MSN
Nektar Therapeutics Announces Closing of $115 Million Public Off - GuruFocus
Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - WV News
Nektar Raises $115M in Oversubscribed Offering: Major Boost for Immunotherapy Drug Development - Stock Titan
Nektar Therapeutics Prices $100 Million Common Stock Offering - MarketScreener
Nektar Therapeutics launches proposed public offering - MSN
Nektar Therapeutics Announces Public Offering of Shares - TipRanks
Nektar Therapeutics (NKTR) Launches Public Offering - GuruFocus
Nektar Therapeutics (NKTR) Stock Dips Amid $100M Offering - GuruFocus
Nektar Therapeutics Announces Pricing of $100 Million Public Off - GuruFocus
Nektar Therapeutics dips after announcing equity offering - TradingView
Nektar Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Nigeria
Nektar Therapeutics Announces Proposed Public Offering | NKTR Stock News - GuruFocus
Nektar Therapeutics Announces Proposed Public Offering - WV News
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? - The Globe and Mail
REZOLVE-AD and Rezpegaldesleukin for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD, MPH - HCPLive
Vital Signs: Nektar's Dupixent challenger comes better late than never - FirstWord Pharma
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside - MSN
Why Nektar Therapeutics Stock Was Red-Hot Today - MSN
Nektar Therapeutics Leads Stock Market Frenzy With Impressive Gains - Finimize
Nektar Therapeutics (NKTR) Surges After Positive Drug Trial Results - GuruFocus
Nektar (NKTR) Receives Significant Price Target Upgrade | NKTR S - GuruFocus
Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today? - TipRanks
Nektar Therapeutics Soars 156.5% on Positive Atopic Dermatitis Study Results - AInvest
Rezpegaldesleukin: Nektar's Treg Activator Poised to Transform Atopic Dermatitis Treatment - AInvest
Nektar Therapeutics: Rezpegaldesleukin's Breakthrough in Atopic Dermatitis Drives Biotech Innovation and Market Potential - AInvest
Nektar Therapeutics stock soars on upcoming atopic dermatitis data By Investing.com - Investing.com South Africa
0.87%
0.17%
자본화:
|
볼륨(24시간):